Meet the Doctors
Nathan Bahary, MD, Ph.D., a medical oncologist, was most recently the Medical Director of the Pancreatic Cancer Program, Co-Director of the UPMC Pancreatic Cancer Center of Excellence and Co-Director of the UPMC Phase II program. He is known for his research and clinical activities in the field of gastrointestinal cancers in general, and particularly in pancreatic cancer.
Dr. Bahary earned his MD degree at the Cornell University School of Medicine and his PhD in genetics at Rockefeller University. He served a clinical fellowship at Harvard Medical School, was an intern and resident at Beth Israel Hospital, and did postdoctoral work at Dana-Farber Cancer Institute and Brigham and Women’s Hospital.
Building on his work at Harvard Medical School, Dr. Bahary is using insights gained by studying vertebrate development to determine how cancers grow. Clinical trials emanating from this research will continue at AHN Cancer Institute, and are expected to lead to the development of new targeted agents and immunologic strategies for treating cancer. At AHN Cancer Institute, he will serve in the roles of Academic Chief of Medical Oncology and Director of the AHNCI clinical research program.
MD, Ph.D
Nathan Bahary
Dr. Bahary’s research has looked at vertebrate development to determine how cancers grow. Those observations will lead to clinical trials at AHN that are expected to yield new targeted agents and immunological strategies for treating cancer. He is a member of the NCI Pancreatic Task Force, Eastern Cooperative Oncology Group, and the American Society of Clinical Oncology, just to name a few. He has received numerous awards and recognitions, including the prestigious PCRT Award of Excellence and the National Pancreas Foundation Courage Award.
MD, PhD, Academic Chief of Medical Oncology and Director of AHN Cancer Institute’s clinical research program
Meet the Doctors
Meet the Doctors
Dr. Beriwal focuses on high-dose brachytherapy for cervix, uterine, vaginal, and breast cancers. He also researches prostate seed implantation, image-guided radiation, and intensity-modulated radiation therapy. He is a fellow of the American Brachytherapy Society and been an integral part of formulating the organization’s guidelines for management of cervix, endometrium, and vaginal cancer. His current clinical research includes 3D image-based brachytherapy and outcome analysis for breast, prostate, and gynecological cancers.
MD, MBA, Academic Chief of Radiation Oncology
Sushil Beriwal
Dr. Beriwal focuses on high-dose brachytherapy for cervix, uterine, vaginal, and breast cancers. He also researches prostate seed implantation, image-guided radiation, and intensity-modulated radiation therapy. He is a fellow of the American Brachytherapy Society and been an integral part of formulating the organization’s guidelines for management of cervix, endometrium, and vaginal cancer. His current clinical research includes 3D image-based brachytherapy and outcome analysis for breast, prostate, and gynecological cancers.
MD, MBA
Meet the Doctors
Meet the Doctors
Dr. Dietz is a nationally recognized breast surgeon. She recently completed a two-year term as President of the American Society of Breast Surgeons, where she spearheaded the creation of a robust virtual education platform for the organization’s 3,200 members. She also formed the COVID-19 Pandemic Breast Cancer Consortium, pulling together cancer leaders from all over the country to quickly publish “Guidelines for the Prioritization and Treatment of Breast Cancer during the Pandemic.” And Dr. Dietz co-developed the “Global Breast Hub,” the first worldwide platform for the gathering and sharing of data and best practices to address gaps in breast cancer care.
MD, FACS, Chief Transformation Officer and Director of Breast Growth and Strategy
Jill Dietz
Prior to joining AHN Cancer Institute, Dr. Dietz served as Director of Breast Center Operations at University Hospitals Case Medical Center and Associate Professor of Surgery at Case Western Reserve University School of Medicine. Dr. Dietz previously led breast centers at Washington University, Barnes Jewish Hospital, the Cleveland Clinic and University Hospitals of Cleveland. She also served as Chief Quality and Allocation Officer for the Cleveland Clinic ambulatory surgery centers, and as principal at TrueNorth Medical Consulting, she serves as a consultant for breast centers around the world.
Dr. Dietz just completed a two-year term as President of the American Society of Breast Surgeons, during which she led the development of a robust virtual education platform for the organization’s 3,200 members. In that capacity, she also formed the COVID-19 Pandemic Breast Cancer Consortium, gathering leaders from major national cancer organizations to expeditiously publish “Guidelines for the Prioritization and Treatment of Breast Cancer during the Pandemic.” Leveraging her national and international reputation and influence in the field of breast surgical oncology, Dr. Dietz also co-developed “Global Breast Hub,” the first global platform for gathering and sharing data and best practices to decrease gaps in breast cancer care.
MD, FACS
Meet the Doctors
Meet the Doctors
Dr. Bartlett is a renowned cancer researcher and clinician who specializes in advanced surgical treatments for abdominal cancers He is well known for his work to modernize a method of hyperthermic intraperitoneal chemoperfusion (HIPEC) therapy, in which chemotherapeutic drugs are heated and delivered directly to the abdominal cavity to target and eradicate cancer cells. For the last 25 years, he has also been researching ways in which some replicating viruses can be trained or mutated to selectively damage, injure, and kill cancer cells.
MD, Chair AHN Cancer Institute
David L. Bartlett
Dr. Bartlett joined AHN in May 2020 as Chair of AHN Cancer Institute and began his AHN surgical practice at Saint Vincent Hospital in Erie. He will continue to see patients in Erie, in addition to his Pittsburgh practice.
Dr. Bartlett came to AHN from the University of Pittsburgh Medical Center, where he held several leadership positions in research and surgical oncology. A graduate of the University of Texas School of Medicine, Dr. Bartlett completed a residency in general surgery at the Hospital of the University of Pennsylvania, in Philadelphia, and a fellowship in surgical oncology at Sloan-Kettering Cancer Center in New York. He also performed clinical research at MD Anderson Cancer Center in Houston.
Dr. Bartlett helped to develop and refine new regional perfusion techniques, including the modern version of the hyperthermic intraperitoneal chemoperfusion (HIPEC) therapy, in which chemotherapeutic drugs are heated and delivered directly into the abdominal cavity in an effort to eradicate cancer cells. He is also known for his cutting-edge research into viral-based immune therapies.
MD